Form 4: Astria Therapeutics Director Michael Kishbauch Acquires Stock Options
SEC Form 4
Director Michael Kishbauch of Astria Therapeutics, Inc. reports the acquisition of stock options on June 5, 2024.
Summary
- Michael Kishbauch, a director of Astria Therapeutics, Inc., filed a Form 4 disclosing changes in beneficial ownership.
- On June 5, 2024, Kishbauch acquired 14,100 stock options with an exercise price of $9.18.
- These options vest in full on June 5, 2025, contingent upon continued service as a director.
- Following the transaction, Kishbauch directly owns 14,100 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock option grant and transaction. |
| 06/05/2025 | Vesting date of the stock options. |
| 06/04/2034 | Expiration date of the stock options. |
| 06/06/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.